In other news, on the Kluwer Patent Blog last week Mike Gruber reported on the German Patent Court’s November 21 decision ordering Merck to pay a 4% royalty to Shionogi for a compulsory license to use the drug Isentress. I previously reported on the German Federal Supreme Court’s decision …
